BOSTON--(BUSINESS WIRE)--Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management Solution™ (eGMS™) have been selected as poster presentations at the American Diabetes Association 75th Scientific Sessions. The 75th Scientific Sessions, taking place from June 5-9th in Boston, are the premier venue for exchanging news and showcasing innovation to the diabetes community.
At the conference, Glytec will be displaying more evidence of improved subcutaneous and IV insulin management using Glytec’s eGMS, following the release of ten studies in May. eGMS provides clinician-developed, algorithm-based software (GlucommanderTM) designed to consider insulin sensitivity and individualize dosing recommendations to address and prevent excursions through all aspects of insulin therapy.
"The ADA brings together the best and most innovative research to improve care for patients with diabetes, and we were honored to be able to present several clinical studies at the 2015 meeting," said Raymie McFarland, Vice President of Quality Initiatives at Glytec. "Reducing the incidence of hypoglycemia during insulin treatment is critically important, yet often difficult to achieve, especially with certain patient populations. This latest round of studies focused on patients with end stage renal disease, kidney transplants, stress or medication induced hyperglycemia without diabetes, and patients undergoing a bone marrow transplant."
The following scientific posters will be presented at the conference:
- “Use of eGlycemic Management System Safely Achieves Optimal Subcutaneous Glycemic Control with Low Hypoglycemia in Patients without Diabetes – This poster showcases that, by leveraging Glytec’s Glucommander, patients without a diagnosis of diabetes on admission or post discharge were able to achieve target glucose with no severe hypoglycemia and lower incidence of mild hypoglycemia compared to standard order sets.
- “eGlycemic Management System Safely Achieves Rapid and Sustained Glycemic Control in Kidney Transplant Patients and Reduces Risk of Hypoglycemia Compared to Standard Treatment Protocols” – This poster details that renal transplant patients treated with Glucommander achieved a higher percentage of target blood glucose results, lower mean glucose levels, less hypoglycemia, and lower glucose variability compared to patients on standard order sets.
- “Patients with Kidney Disease Reach Target Glucose with Low Incidences of Hypoglycemia When IV Insulin is Managed on eGlycemic Management System Glucommander” – This study demonstrates that patients with kidney disease can reach target glucose in a reasonable timeframe with a very low incidence of hypoglycemia using Glucommander.
- “Finding the Sweet Spot in Bone Marrow Transplant Patients – eGlucose Management System in Allogenic Hematopoietic Cell Transplant” – This study showcases that tight control of blood glucose in hematopoietic cell transplant (HCT) patients using Glytec’s eGMS is feasible, despite high-doses of steroids, total parenteral nutrition (TPN), and unpredictable oral intake.
“The treatment of steroid-induced hyperglycemia during graft vs. host disease in bone marrow transplant patients on the surface seems like it would be important. Up until now, most thought it would be difficult to even consider a clinical trial to assess if glucose control could impact outcomes – including mortality – because our insulin protocols were not robust enough to deal with the high-dose steroids, TPN, and occasional eating all at the same time,” said Irl B. Hirsch, MD, Professor of Medicine at University of Washington Medical Center – Roosevelt. “The Glucommander showed in our feasibility trial it is indeed possible to control glycemia in this population.”
For more information regarding the ADA 75th Scientific Sessions, please visit http://adascisessions.civi-go.com/meetings/program-information
Founded in 2006, Glytec is a rapidly growing digital heath company specializing in advanced technology for diabetes management. eGMS™, Glytec’s glycemic management information system, enables providers, payers and patients to significantly reduce the frequency, risks and costs of hyperglycemia and hypoglycemia. The cloud based, modular eGMS™ centers on the Glucommander Suite™ of FDA-cleared, predictive dosing algorithms for IV, subcutaneous and pediatric dosing: Glucommander IV™ (FDA clearance 2006), Glucommander SubQ™ (FDA clearance 2010) and Glucommander Pediatrics™ (FDA clearance 2012). Comprehensive management of patients requiring insulin therapy is further enabled by seamless EHR integration (SmartClick™) and robust analytics (Glucometrics™) and surveillance (GlucoSurveillance™) capabilities. The unique breadth and depth of the eGMS* interventional clinical decision support tools allows providers to standardize its process and individualize treatment across all areas of care, and is proven to result in significant improvements in clinical and financial outcomes versus traditional methods. For more information, please visit http://www.glytecsystems.com/
*Multiple patents pending